I’ll let the following fact speak for itself whilst I ponder if it’s time for the CEO to resign or be replaced:
The day after Jackie Fairley was appointed to the newly created role of Starpharma Chief Operating Officer (she subsequently became CEO a year later) the SPL share price opened trading at 68 cents.
17 years later, Jackie Fairley is still at the helm as CEO and the SPL share price is 63 cents. Five cents lower.
This has been an outrageously horrible performing investment in anyone’s language. In this time directors have come and gone, executives have come and gone, CFOs and Chairmen have come and gone. There has only been one constant, and that is CEO Fairley.
IMO I cannot fathom how she still keeps her job with the missteps (regulatory issues and fines), delayed completion of trials, slow developments, poor share price performance, a significant salary and all the while, a leave pass to also work for other companies such as ASX listed Mirrabooka Investments.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)